公开(公告)号：US10287299B2

公开(公告)日：2019-05-14

申请号：US15580059

申请日：2016-06-07

Applicant: UCB Biopharma SPRL

Inventor： Gareth Neil Brace ,  Prafulkumar Tulshibhai Chovatia ,  Gregory Foulkes ,  James Andrew Johnson ,  Severine Danielle Jones ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  Pui Leng Loke ,  Martin Alexander Lowe ,  Ajay Mandal ,  Timothy John Norman ,  Christopher Francis Palmer ,  Yolanda Pérez-Fuertes ,  John Robert Porter ,  Donald Smyth ,  Giancarlo Trani ,  Muhammed Uddin ,  Zhaoning Zhu

IPC: A61K31/5365 ,  C07D265/36 ,  C07D498/04 ,  C07D401/06 ,  C07D413/06 ,  A61P27/02 ,  A61P3/00 ,  A61P9/00 ,  A61P23/00 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61K31/423 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/55 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D519/00

Abstract: A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20160304511A1

公开(公告)日：2016-10-20

申请号：US15100915

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Victoria Elizabeth Jackson ,  Fabien Claude Lecomte ,  John Robert Porter

IPC: C07D471/04 ,  A61K31/437

CPC classification number: C07D471/04 ,  A61K31/437

Abstract: A series of substituted 1H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20160297795A1

公开(公告)日：2016-10-13

申请号：US15038287

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Jag Paul Heer ,  Victoria Elizabeth Jackson ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  John Robert Porter

IPC: C07D401/10 ,  A61K31/4439

CPC classification number: C07D401/10 ,  A61K31/4439 ,  C07D235/12

Abstract: A series of substituted 4,5,6,7-tetrahydrobenzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列取代的4,5,6,7-四氢苯并咪唑衍生物有益于治疗和/或预防各种人类疾病，包括自身免疫性和炎症性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。

公开(公告)号：US09309243B2

公开(公告)日：2016-04-12

申请号：US14414287

申请日：2013-07-05

Applicant: UCB Biopharma SPRL

Inventor： Jonathan Mark Bentley ,  Daniel Christopher Brookings ,  Julien Alistair Brown ,  Thomas Paul Cain ,  Praful Tulshi Chovatia ,  Anne Marie Foley ,  Ellen Olivia Gallimore ,  Laura Jane Gleave ,  Alexander Heifetz ,  Helen Tracey Horsley ,  Martin Clive Hutchings ,  Victoria Elizabeth Jackson ,  James Andrew Johnson ,  Craig Johnstone ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  Deborah Leigh ,  Martin Alexander Lowe ,  James Madden ,  John Robert Porter ,  Joanna Rachel Quincey ,  Laura Claire Reed ,  James Thomas Reuberson ,  Anthony John Richardson ,  Sarah Emily Richardson ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Zhaoning Zhu

IPC: C07D491/02 ,  C07D471/04 ,  C07D519/00 ,  A61K31/437 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/5513 ,  A61K31/554 ,  C07D491/107

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/5513 ,  A61K31/554 ,  C07D491/107 ,  C07D519/00

Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列式（I）的咪唑并[1,2-a]吡啶衍生物因此有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。